Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors

Lin, Vincent; Blaylock, Barbara; Jb, Epstein; Purdum, Anna G.

doi:10.1080/03007995.2018.1474091

Cited by 10 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparisons with other long-term survivor groups are challenging, since there are few similar populations of patients with advanced disease and durable survival. Such populations might include survivors of lymphoma, in whom findings regarding QoL are mixed, 31 and breast cancer, whose overall QoL appears comparable to controls but who may report impediments in functioning. 32 In our study, global QoL exceeded that Open access reported for the general population (median global health status 83 compared with 75 in the general population).…”

Section: Open Accessmentioning

confidence: 99%

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors

Mamoor

Postow

Baxi

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (CIs) have revolutionized treatment of advanced melanoma, leading to an emerging population of long-term survivors. Survivors’ quality of life (QOL) and symptom burden are poorly understood. We set out to evaluate symptom burden and QOL in patients with advanced melanoma alive more than 1 year after initiating CI therapy.MethodsCross-sectional surveys, accompanied by chart review of patients with advanced melanoma treated with CIs at Memorial Sloan Kettering Cancer Center, completed therapy, and were alive >1 year after treatment initiation. Surveys were administered between February and August 2018. Surveys included: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, EuroQOL, items from Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events and Fatigue Severity Scale.ResultsWe included 90 patients. The most common CI regimens were ipilimumab plus nivolumab (53%) and pembrolizumab (41%); most patients (71%) were not treated in clinical trials. Median time from CI therapy initiation was 40 months and from last dose was 28 months. Fatigue was reported by 28%, with higher fatigue scores in women than men; 12% reported difficulty sleeping. Aching joints (17%) and muscles (12%) were fairly common. Level of functioning was generally high. Overall QOL was excellent though 40% reported ‘some or moderate’ problems with anxiety/depression and 31% with pain/discomfort.ConclusionsAfter CI therapy, long-surviving advanced melanoma patients commonly report fatigue but otherwise have moderate symptom burden and good QOL. Ensuring appropriate symptom management will optimize clinical outcomes for these patients.

show abstract

Section: Open Accessmentioning

confidence: 99%

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors

Mamoor

Postow

Baxi

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…In comparison, our review presented 82 EQ-5D-based HSUVs within the same clinical field. Other systematic reviews either aimed at HSUV identification in patients with hematologic diseases or failed to present any values (NHL survivors at least 2 years from diagnosis) 121 or else found a very limited number (2 HSUVs for AML patients not eligible for intensive chemotherapy). 122 Until now, the classic source of health utilities in this area was Pickard et al's publication from 2007, which was a systematic review of HSUVs in oncology, including 6 studies presenting 17 HSUVs for patients with leukemia, HM, NHL, or MM.…”

Section: Discussionmentioning

confidence: 99%

EQ-5D–Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review

Golicki

Jaśkowiak²,

Wójcik³

et al. 2020

Value in Health

View full text Add to dashboard Cite

Objectives: We performed a systematic review of health state utility values (HSUVs) obtained using the EQ-5D questionnaire for patients with hematologic malignancies. Methods:The following databases were searched up to September 2018: MEDLINE, EMBASE, The Cochrane Library, and the EQ-5D publications database on the EuroQol website. Additional references were extracted from reviewed articles. Only studies presenting EQ-Index results were incorporated. In view of the heterogeneity across the included publications, we limited ourselves to a narrative synthesis of original HSUVs found.Results: Fifty-nine studies (described in 63 articles) met the inclusion criteria. Data from 21 635 respondents provided 796 HSUV estimates for hematologic malignancy patients. EQ-Index scores ranged from -0.025 to 0.980. The most represented area was multiple myeloma (4 studies, 11 112 patients, and 249 HSUVs). In clinical areas such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and mantle cell lymphoma, we described over 50 health utilities in each. In contrast, we identified only 13 HSUVs (based on 4 studies and the data of 166 patients) for Hodgkin lymphoma. Areas without EQ-5D-based health utilities comprised: polycythemia vera, primary myelofibrosis, essential thrombocythemia, mastocytosis, myeloid sarcoma, chronic myelomonocytic, eosinophilic leukemia, and neutrophilic leukemia. Conclusions:There is a wide range of HSUVs available for hematologic cancer patients with different indications. The review provides a catalog of utility values for use in cost-effectiveness models for hematologic malignancies.

show abstract

“…Diagnosis and staging of lymphoma may involve several tests including PET (positron emission tomography) scan and CT (computerised tomography) scan, and bone marrow biopsy; and lymphoma treatments can range from watchful waiting to intensive treatments including chemotherapy, radiation therapy, novel treatments and/or stem cell transplant 2 . Indeed, psychological distress is recognised as a prevalent issue among cancer patients/survivors 7 and emerging research suggests that lymphoma patients/survivors can have significantly impaired psychological wellbeing and health‐related quality of life (HRQOL) 8–13 …”

Section: Introductionmentioning

confidence: 99%

“…Existing systematic reviews have mainly synthesised studies of HRQOL in this population 8–11,17,18 . However, being one domain of a broad and multidimensional HRQOL, emotional distress is rarely discussed extensively in these reviews.…”

Section: Introductionmentioning

confidence: 99%

Factors of emotional distress in lymphoma: A systematic review

2023

View full text Add to dashboard Cite

Objective Distress is prevalent among lymphoma patients/survivors. Current processes of distress identification rely on self‐reporting by patients/survivors, which may be limited by their willingness to report symptoms. To help identify patients/survivors at greater risk, this systematic review aims to comprehensively review factors that may contribute to distress in lymphoma patients/survivors. Methods PubMed was systematically searched for peer‐reviewed primary articles (1997–2022) consisting of standardised keywords “lymphoma” and “distress.” Information from 41 articles was integrated via narrative synthesis. Results Consistent risk factors of distress include younger age, relapsed disease, and greater comorbidities and symptom burden. Active treatment and the transition from treatment to post‐treatment could be challenging phases. Adequate social support, adaptive adjustment to cancer, engaging in work and healthcare professionals' support may mitigate distress. There is some evidence that older age may be associated with greater depression and life changes/experiences may shape how individuals cope with lymphoma. Gender and marital status were not robust predictors of distress. Other clinical, psychological and socioeconomic factors are understudied or have mixed findings. Conclusions While several factors of distress align with that of other cancers, more research is needed to identify significant factors of distress in lymphoma patients/survivors. The identified factors may support clinicians in identifying distressed lymphoma patients/survivors and providing interventions where necessary. The review also highlights avenues for future research and a need to routinely collect data on distress and its factors in registries.

show abstract

Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors

Abstract: HRQoL of NHL survivors may improve from baseline and becomes more comparable to general population HRQoL with longer survival. Overall HRQoL improvement is driven mostly by improvements in the physical domain.

Cited by 10 publications

References 21 publications

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors

EQ-5D–Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review

Factors of emotional distress in lymphoma: A systematic review

Contact Info

Product

Resources

About